J
John Bridgewater
Researcher at University College London
Publications - 234
Citations - 20892
John Bridgewater is an academic researcher from University College London. The author has contributed to research in topics: Cancer & Colorectal cancer. The author has an hindex of 42, co-authored 197 publications receiving 15582 citations.
Papers
More filters
Journal ArticleDOI
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
Thierry André,Corrado Boni,Lamia Mounedji-Boudiaf,Matilde Navarro,Josep Tabernero,Tamas Hickish,C. Topham,Marta Zaninelli,Phillip Clingan,John Bridgewater,Isabelle Tabah-Fisch,Aimery de Gramont +11 more
TL;DR: Adding oxaliplatin to a regimen of fluorouracil and leucovorin improves the adjuvant treatment of colon cancer.
Journal ArticleDOI
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Juan Ignacio Valle,Harpreet Wasan,Daniel H. Palmer,David Cunningham,Alan Anthoney,Anthony Maraveyas,Srinivasan Madhusudan,Timothy Iveson,Sharon M. Hughes,Stephen P. Pereira,M Roughton,John Bridgewater +11 more
TL;DR: Cisplatin plus gemcitabine is an appropriate option for the treatment of patients with advanced biliary cancer and was associated with a significant survival advantage without the addition of substantial toxicity.
Journal ArticleDOI
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
Thierry André,Corrado Boni,Matilde Navarro,Josep Tabernero,Tamas Hickish,C. Topham,Andrea Bonetti,Philip Clingan,John Bridgewater,Fernanado Rivera,Aimery de Gramont +10 more
TL;DR: Adding oxaliplatin to LV5FU2 significantly improved 5-year DFS and 6-year OS in the adjuvant treatment of stage II or III colon cancer and should be considered after surgery for patients with stage III disease.
Journal ArticleDOI
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
John Bridgewater,Peter R. Galle,Shahid A. Khan,Josep M. Llovet,Joong-Won Park,Tushar Patel,Timothy M. Pawlik,Gregory J. Gores +7 more
TL;DR: University College, London Cancer Institute, 72 Huntley St.
Journal ArticleDOI
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Jesus M. Banales,Jesus M. Banales,Jesus M. Banales,Jose J.G. Marin,Jose J.G. Marin,Angela Lamarca,Angela Lamarca,Pedro M. Rodrigues,Shahid A. Khan,Lewis R. Roberts,Vincenzo Cardinale,Guido Carpino,Jesper B. Andersen,Chiara Braconi,Diego F. Calvisi,Maria J. Perugorria,Maria J. Perugorria,Luca Fabris,Luca Fabris,Luke Boulter,Rocio I.R. Macias,Rocio I.R. Macias,Eugenio Gaudio,Domenico Alvaro,Sergio A. Gradilone,Mario Strazzabosco,Mario Strazzabosco,Marco Marzioni,Cédric Coulouarn,Laura Fouassier,Chiara Raggi,Pietro Invernizzi,Joachim C. Mertens,Anja Moncsek,Sumera Rizvi,Julie K. Heimbach,Bas Groot Koerkamp,Jordi Bruix,Jordi Bruix,Alejandro Forner,Alejandro Forner,John Bridgewater,Juan W. Valle,Juan W. Valle,Gregory J. Gores +44 more
TL;DR: This expert Consensus Statement, endorsed by the ENS-CCA, summarizes the latest advances in CCA, including classification, genetics and treatment, and provides recommendations for CCA management and priorities across basic, translational and clinical research.